Lung Cancer News

The University of Texas MD Anderson Cancer announced Thursday the launch of the James P. Allison Institute, a research and innovation hub that integrates immunobiology across disciplines to accelerate discoveries toward cancer cures.

The FDA issued a complete response letter indicating it cannot approve a biologics license application for sintilimab in combination with chemotherapy for first-line treatment of advanced nonsquamous non-small cell lung cancer.

Cancer screening remains in need of urgent attention, and online resources may help facilities close gaps and address screenings missed in 2020, according to a prospective quality improvement study published in Cancer.

Obesity and diffusing capacity of the lungs for carbon monoxide were significant risk factors for home oxygen use after pulmonary resection surgery, according to data published in Annals of the American Thoracic Society.

H. Jack West, MD, medical oncologist at City of Hope, spoke with Healio about AccessHope.

As important as the care of Ukrainian citizens with cancer is to clinicians in that country, this priority has been overshadowed by more immediate concerns.

In the United States, 47.1 million adults reported using commercial tobacco products in 2020, including 30.8 million adults who reported smoking cigarettes, according to data published in Morbidity and Mortality Weekly Report.

Pembrolizumab significantly extended DFS among patients with completely resected stage IB to stage III non-small cell lung cancer, irrespective of PD-L1 expression, according to a study presented during an ESMO Virtual Plenary session.

Healio spoke with Peter J. Mazzone, MD, MPH, director of the Lung Cancer Program and Lung Cancer Screening Program at the Cleveland Clinic Cancer Center Respiratory Institute, about how the 2021 changes to the USPSTF lung cancer screening guidelines have affected the number of patients being screened, improvements in patient outcomes and how specialists should continue to prepare for the effects of the updated guidelines.

The FDA approved FoundationOne CDx as a companion diagnostic to guide treatment selection for certain patients with non-small cell lung cancer.